RMD
🔒 LOCKEDResMed Inc.
🔒 Unlock Full Analysis
Sign in and use 1 credit to see AI verdict, intrinsic value, SWOT analysis, and all premium insights.
AI Executive Summary
ResMed is a leading medical device company specializing in sleep and respiratory disorders, poised for growth due to an aging population and increasing adoption of AI in healthcare.
The Business DNA
ResMed develops and distributes medical devices and cloud-based software for respiratory disorders, primarily sleep apnea. The company benefits from a strong competitive position due to its established brand, innovative products, and extensive distribution network. They operate in two segments: Sleep and Breathing Health, and Residential Care Software. Recent news highlights ResMed's favorable position within the medical products industry.
Financial Health
Valuation Analysis
With a PE ratio of 24.9 and a forward PE of 20.7, ResMed's valuation appears reasonable given its growth prospects. The price-to-sales ratio of 6.8 suggests a premium valuation, reflecting the company's profitability and market leadership. Considering the target mean price of $297.47, the stock appears undervalued at its current price.
Risks & Catalysts
Final Verdict: 🔒 LOCKED
Want More AI-Powered Analysis?
Get unlimited stock analyses, portfolio tracking, and real-time alerts
Related Stock Analyses
This analysis is generated by AI and should not be considered financial advice. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Last updated: 3/16/2026